Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab: - PMR RR 3.8x N/I vs. P - no diff in GCA risk @RheumNow #ACR24 https://t.co/IF4Gh7Cumd